Desogestrel for the Preoperative Treatment of Endometrioma Compared With Placebo

The Use of Oral Desogestrel for the Preoperative Treatment of Endometrioma Compared With Placebo : A Randomized Controlled Trial Evaluation of the Effect on Cyst Diameter and Associated Pain

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04941833

Enrollment

Registered

2021-06-28

Start date

2021-06-01

Completion date

2022-09-30

Last updated

2022-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrioma

Brief summary

Use of the oral desogestrel compared with placebo for preoperative treatment of endometrioma in the patient who underwent to surgery in next 3 months The result will be evaluated on cyst diameter, the associated pain and side effect of the oral desogestrel.

Detailed description

Use of the oral desogestrel compared with placebo for preoperative treatment of endometrioma in the patient who underwent to surgery in next 3 months in Rajvithi hospital Patient will randomized in 2 group : Desogestrel and placebo After 1 months and 3 months the patient have to come to hospital to evaluate the result of study The result will be evaluated on cyst diameter, the associated pain and side effect of the oral desogestrel.

Interventions

DRUGDesogestrel Oral Tablet

Cerazette is the brand name of the desogestrel which contain of 0.075 mg of desogestrel

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

FEMALE

Age

15 Years to 49 Years

Healthy volunteers

Yes

Inclusion criteria

* Thai female and foreigner who can understand Thai language * Age 15-49 years * Diagnose as endometrioma sized more than 3 cm * Underwent to surgery in next 13 weeks

Exclusion criteria

* History of endometriosis * Pregnancy woman * Contraindication for desogestrel : History of thrombotic event, Autoimmune disease,gestational trophoblastic disease * Ovarian endometrioma with complications : Ruptured, twisted * Contraindications for NSAIDs : Peptic ulcer, thrombocytopenia, liver disease * History of hormonal treatment for endometrioma : DMPA,OCP, GNRH agonist/antoginist

Design outcomes

Primary

Measure	Time frame	Description
Cyst diameter	3 months after drug given	Cyst diameter is calculated by transvaginal ultrasound with calculated in the diameter of endometrimas (cm)

Secondary

Measure	Time frame	Description
Associated pain	3 months after drug given	Associated pain is measured by the visual analog score. The patients will record the score on the book everytimes when they have pain

Other

Measure	Time frame	Description
Effect of the drug in the study	3 months after drug given	Effect of the oral desogestrel and placebo such as spotting, weight gain, wood swing

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026